Cost Effective Personalised Compression Therapy for Chronic Venous Insufficiency with Accurate Pressure Delivery for Comfort and Efficacy of Treatment

Información del proyecto

ISOBAR

Identificador del acuerdo de subvención: 736205

DOI

10.3030/736205

Proyecto cerrado

Fecha de la firma de la CE 12 Julio 2016

Fecha de inicio 1 Agosto 2016

Fecha de finalización 31 Enero 2017

Financiado con arreglo a

• INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Nanotechnologies

Coste total

€ 71 429,00

Aportación de la UE

€ 50 000,00

Coordinado por

ADVANCED THERAPEUTIC MATERIALS LTD
United Kingdom

Periodic Reporting for period 1 - ISOBAR (Cost Effective Personalised Compression Therapy for Chronic Venous Insufficiency with AccuratePressure Delivery for Comfort and Efficacy of Treatment)

Período documentado: 2016-08-01 hasta 2017-01-31

Resumen del contexto y de los objetivos generales del proyecto

The ISOBAR concept is based on a novel approach of compression therapy delivery, which is essential for successful treatment and management of many common circulatory disorders (Chronic venous insufficiency, Lymphoedema and DVT prophylaxis). Chronic venous insufficiency (CVI) is a condition in which the blood, which normally would flow back to the heart from the veins in the lower limbs, does not do so efficiently because the valves in the veins are damaged or absent. It affects up to 50% of the adult population, and it is estimated that 1% of the UK population will suffer from leg ulceration during their lifetime. It is estimated that the annual cost of treatment for CVI in the European Union is €6.5 billion, and in the UK only the annual cost is up to €850 million.

Trabajo realizado desde el comienzo del proyecto hasta el final del período abarcado por el informe y los principales resultados hasta la fecha

The ISOBAR technology is currently at TRL 7. After reviewing all of the information available on the vascular healthcare market, we have concluded that the European market, especially UK, France and Italy, will be the main focus for ISOBAR technology commercialization for the next 3 years. We have also evaluated potential partners for the software development (Imfusion GmbH, Germany). In addition, we identified ANR Manufacturing from Buckinghamshire, UK as a partner to assemble scanners from parts specified by ATM. We compiled a business plan, and as part of that, we created a risk analysis to help to form the basis for a Phase 2 application. ATM will therefore proceed with our plans to carry out the development project and submit a Phase 2 application to continue the route to commercialisation.

Avances que van más allá del estado de la técnica e impacto potencial esperado (incluida la repercusión socioeconómica y las implicaciones sociales más amplias del proyecto hasta la fecha)

The ISOBAR technology will offer a novel approach of compression therapy delivery with a structured compression garment that fits a patient precisely and delivers the prescribed pressure. Once fully developed, it will resolve all the problems associated with the current techniques and systems for delivering compression therapies. The problems associated with the current methods: difficult applications and frequent measurement errors, constant supervision by trained clinicians required, numerous issues with therapy delivery, low pressure delivery and design problems, social isolation for the patients.

Scanner with separate processing screenshots